Form 4: Cabaletta Bio Executive Receives Option Repricing

David J. Chang, Chief Medical Officer of Cabaletta Bio, Inc., receives repriced stock options effective May 19, 2025.

Summary

• David J. Chang, the Chief Medical Officer of Cabaletta Bio, Inc., has been granted repriced stock options.
• The repricing was approved by the Issuer's board of directors on May 15, 2025, and became effective on May 19, 2025.
• The exercise price of the options has been adjusted to $1.92 per share, reflecting the fair market value of Cabaletta Bio's common stock on the repricing date.
• Chang received multiple grants of options at the new price of $1.92, and had existing options repriced.
• The repriced options are subject to a retention period, during which the original exercise price will apply if exercised.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction. The repricing itself could be seen as slightly positive for incentivizing management, but also potentially concerning if the stock price has underperformed.

Positives

• The option repricing may incentivize the Chief Medical Officer to remain with the company.
• The repricing aligns the executive's interests with those of shareholders by reflecting the current market value of the stock.

Risks

• If the executive leaves the company before the end of the retention period, the benefit of the repricing may be lost.
• The repricing could be perceived negatively by shareholders if the stock price does not improve.

Industry Context

Option repricing is a common practice in the biotech industry to retain and incentivize key executives, especially when a company's stock price has declined.

Comparison to Industry Standards

• Comparing Cabaletta Bio's executive compensation practices to those of similar-sized biotech companies like Arcellx, Inc. and Cartesian Therapeutics, Inc. shows that option grants and repricing are standard tools for incentivizing key personnel.
• The specific terms of the repricing, such as the retention period, are also common features designed to ensure continued service and alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the repricing as a positive incentive for the Chief Medical Officer, or negatively if they believe it rewards underperformance.
• Employees may see the repricing as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Cabaletta Bio, David J. Chang, repricing, executive compensation, Form 4